High Blood Pressure Medicine Maker Settles Claims for $300 Million
In recent news, drug manufacturer Daiichi Sankyo agreed to a $300-million settlement for those suffering at the hands of commonly-prescribed high blood pressure medication, olmesartan, for failure to adequately warn patients about drug risks. Dangerous drugs remain in-use for high blood pressure patients, and the St. Louis personal injury attorneys at Hoffman & Gelfman want you to know:
Company Admits Liability, Yet Insists Drug Safe
Olmesartan, sold under brand names Tribenzor, Olmetec, Benicar, Benicar HCT, and Azor, the drug has been linked to severe gastrointestinal problems and even death in over 2,300 lawsuits. The severe intestinal damage, chronic diarrhea, and substantial weight losses suffered by patients using the drug have been identified at-issue since a 2012 Mayo Clinic study.
Further, these problems were erroneously misdiagnosed as celiac disease for a number of years by doctors left in the dark as to the drug’s potential side effects,
Not the First Legal Trouble with the Drug
In 2015, Daiichi Sankyo paid $40-million to the U.S. Dept. of Justice to settle agency allegations the company illegally paid kickbacks to doctors for prescribing the drug over others from 2005-2011.
You Have the Right to File a Lawsuit
You may be entitled to compensation for the life-altering side-effects of olmesartan, including compensation for lost wages, repayment for medical treatment and hospitalization, pain and suffering, and negligence. Contact the St. Louis personal injury attorneys at Hoffman & Gelfman to learn more today.